By bringing a drug that's been well-established as safe in other markets to the U.S. for the first time in order to treat a rare disease, the company doesn't just control its pricing destiny  it will also receive a coveted "priority review voucher" which it can hawk to another firm for tens (or even hundreds) of millions of dollars.